BOTHELL, Wash., June 29 /PRNewswire-FirstCall/ -- Cardiac Science
Corporation (Nasdaq: CSCX), a global leader in automated external
defibrillator (AED) and diagnostic cardiac monitoring devices,
today introduced the remaining versions of software required for
the recall first announced in November, 2009.
(Logo:
http://photos.prnewswire.com/prnh/20080306/AQTH510LOGO)
(Logo:
http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)
The software will enhance the AEDs' self-test capabilities and
improve detection of a rare component-related issue in certain AEDs
manufactured between August, 2003 and August, 2009. The company
announced a recall on these AEDs on November
13, 2009. The affected models include Powerheart 9300A,
9300C, 9300D, 9300E, 9300P, 9390A, 9390E, and CardioVive 92531,
92532, and 92533 devices.
The software update is a mandatory step for customers possessing
these affected devices. The software and update instructions
(available in 36 languages) can be downloaded at
http://www.cardiacscience.com/AED175. Customers with affected AEDs
will be notified by letter regarding the update. Customers with
questions may call or email the company at 877.901.1788 or
AED175@cardiacscience.com.
"This release completes the software development initiative
associated with our November, 2009 recall," said Cardiac Science
President and CEO Dave Marver. "The
software update for a significant portion of affected AEDs was
released in March and we're pleased to now release the update for
the remaining device population. We encourage users with an
affected AED to install the update as soon as possible."
As before, the company advises customers to follow the normal
testing and maintenance procedures found in the Operator and
Service Manual.
If an AED is not rescue ready (the indicator is red), customers
should contact the company immediately at 425.402.2000 (option 1)
within the United States. Outside
the US contact +44.161.926.0011 or the local Cardiac Science
representative.
This release represents the completion of the company's software
development efforts related to the previously announced recall. The
costs associated with this software release are included in the
charges previously announced by the Company.
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of
advanced diagnostic and therapeutic cardiology devices and systems,
including automated external defibrillators (AED),
electrocardiograph devices (ECG/EKG), cardiac stress treadmill and
systems, Holter monitoring systems, hospital defibrillators, vital
signs monitors, cardiac rehabilitation telemetry systems, and
cardiology data management systems (informatics) that connect with
hospital information (HIS), electronic medical record (EMR), and
other information systems. The company sells a variety of related
products and consumables and provides a portfolio of training,
maintenance, and support services. Cardiac Science, the successor
to the cardiac businesses that established the trusted Burdick®,
HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered
in Bothell, Washington. With
customers in more than 100 countries worldwide, the company has
operations in North America,
Europe, and Asia. For information, call 425.402.2000 or
visit http://www.cardiacscience.com.
Forward-Looking Statements
This press release contains forward-looking statements. The word
"believe," "expect," "intend," "anticipate," variations of such
words, and similar expressions identify forward-looking statements,
but their absence does not mean that the statement is not
forward-looking. Forward looking statements in this press release
include, but are not limited to, the scope, capabilities, and
effectiveness of the software update. These are forward-looking
statements for purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995. Actual results
and performance may vary significantly from those expressed or
implied in such statements. Factors that could cause or contribute
to such varying results and other risks are more fully described in
the Annual Report on Form 10-K filed by Cardiac Science Corporation
for the year ended December 31, 2009,
as updated by subsequent quarterly reports on Form 10-Q. Cardiac
Science Corporation undertakes no duty or obligation to update the
information provided herein.
For updates and information on worldwide defibrillation and
cardiac monitoring, find us on the Cardiac Science blog at
http://www.cardiacscience.com/blog, Twitter at
http://twitter.com/cardiacscience, Facebook at
http://budurl.com/CSonFB, YouTube at
http://www.youtube.com/user/CardiacScience.
For more information,
|
|
Cardiac Science
Contact:
|
Investor
Contact:
|
Media Contact:
|
|
Mike Matysik
Cardiac Science
Corporation
Senior Vice President and
CFO
425.402.2009
|
Matt Clawson
Allen & Caron
949.474.4300
matt@allencaron.com
|
Christopher Gale
EVC Group Inc.
646.201.5431
203.570.4681
cgale@evcgroup.com
|
|
|
|
|
|
|
LOGO: http://www.cardiacscience.com/images/main_logo.gif
CSCX-F
SOURCE Cardiac Science Corporation